New generation of antibody drug conjugate (ADC) therapeutics
Spirea has raised €2.9M across 1 funding round from 7 investors, most recently a round in Jun 2022. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-14 | Other | €2.9M |
| ACF investors,Cambridge Angels,Cambridge Enterprise,Jonathan Milner,o2h Ventures,R42 Group+1 more |
| View deal → |
